

Accepted Manuscript

A Word of Caution When Prescribing High Dose Vitamin D

Matthew A. Gorris, MD, Harkesh Arora, MD, David C. Lieb, MD, Joseph A. Aloï, MD



PII: S0002-9343(16)31200-1

DOI: [10.1016/j.amjmed.2016.10.025](https://doi.org/10.1016/j.amjmed.2016.10.025)

Reference: AJM 13786

To appear in: *The American Journal of Medicine*

Received Date: 5 October 2016

Revised Date: 18 October 2016

Accepted Date: 18 October 2016

Please cite this article as: Gorris MA, Arora H, Lieb DC, Aloï JA, A Word of Caution When Prescribing High Dose Vitamin D, *The American Journal of Medicine* (2016), doi: 10.1016/j.amjmed.2016.10.025.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

A Word of Caution When Prescribing High Dose Vitamin D

Authors:

Matthew A. Gorris, MD, Department of Internal Medicine, Wake Forest Baptist Medical Center, Winston Salem, North Carolina, USA

Harkesh Arora, MD, Apogee Physicians, New Mexico, USA

David C. Lieb, MD, Division of Endocrinology, Eastern Virginia Medical School, Norfolk, Virginia, USA

Joseph A. Aloii, MD, Division of Endocrinology, Wake Forest Baptist Medical Center, Winston Salem, North Carolina, USA

Correspondence:

Matthew Gorris, MD
Department of Internal Medicine, Wake Forest Baptist Medical Center
1 Medical center Blvd
Winston Salem, NC 27157
mgorris@wakehealth.edu
248-425-7610(Phone)
336-713-7200 (Fax)

Funding Source: None

Conflicts of Interest Statement: The authors have no conflicts of interest to report. See corresponding conflict of interest document.

As corresponding author, I verify that all authors had access to data and played a role in writing and preparation of the submitted manuscript.

Article Type: Editorial

Key Words: Vitamin D, vitamin D toxicity, supplementation, hypercalcemia

Running Head: High Dose Vitamin D

There has been a significant amount of research investigating the potential benefits of vitamin D supplementation. It is well supported that vitamin D supplementation can reduce risk of fractures and falls. Additionally, there is research proposing vitamin D supplementation is associated with decreased cardiovascular mortality, diabetes, risk of infection, and multiple cancers.¹ With the increase in interest of vitamin D, the amount spent on vitamin D supplements in the United States alone has dramatically increased from \$40 million dollars in 2001 to \$600 million in 2011.² In addition, various formulations and doses are now being used to achieve vitamin D sufficiency.

There is no clear consensus on the safest and most effective regimen to achieve adequate serum 25-hydroxyvitamin D levels. This may be due to large inter-individual variability in response to supplementation. Both intermittent high-dose regimens and daily low dose regimens seem to show similar efficacy in achieving sufficiency.² A popular concept to decrease non-adherence and achieve sufficiency quickly involves using a loading dose followed by a daily maintenance dose. However, the maximum safe bolus is unclear. One of the most popular doses currently is once weekly 50,000 IU of ergocalciferol (D2). While this has gained popularity for its ease of use and fast results, we have seen several cases of vitamin D toxicity and related complications as a result of prescriber error, prescriber and pharmacy communication error, and long term use of high dose vitamin D.

One such case involved an 82 year-old Caucasian woman who presented with nausea and vomiting and was found to have hypercalcemia (14.1 mg/dl). Upon further history and workup it was discovered that the patient had accidentally been taking 50,000 IU of ergocalciferol twice daily. How did this happen? A prescription was inaccurately written for 50 IU twice daily. While we think this was intended to be 500 IU twice daily, the script was interpreted by the pharmacy as 50,000 IU twice daily. Her total 25-hydroxyvitamin D level at the time of diagnosis was 338 ng/ml. The time to toxicity was 5 months. In another case, a 74 year-old obese woman presented with calciphylaxis. She did not have any underlying renal disease, which is often the case with calciphylaxis. Besides her obesity, her only other risk factor was the fact that she had been on 50,000 IU of vitamin D weekly for the past 4 years. While her calcium was only mildly elevated (10.8 mg/dL) and her serum 25-hydroxyvitamin D was only 43 ng/mL, it is believed her long term high dose vitamin D supplementation played a role, as it has been shown to be a risk factor in calciphylaxis.³

With the increase in vitamin D prescribing comes potential for error. Since there is no clear consensus on recommendations for supplementation and monitoring, prescribers are using a variety of approaches to try and achieve vitamin D sufficiency. With the increased use of high dose vitamin D for bolusing, there is potential that these medications could 1) be taken incorrectly or 2) accidentally become a chronic medication. Additionally, higher doses of vitamin D are now being sold over-the-counter, which could lead to patients taking excessive amounts on their own. Occasionally it is not the fault of patients or prescribers, but pharmaceutical companies. There have been cases of manufacturing errors leading to higher than advertised doses of vitamin D in supplements.^{4,5}

This is just a reminder that supplements are not totally benign. Exercise caution when prescribing high dose vitamin D. We would not recommend refilling prescriptions for high dose vitamin D without rechecking a serum 25-hydroxyvitamin D level. It is not meant to be a chronic maintenance dose. Finally, patient education on the various doses may be the most important way to prevent unnecessary or excess supplementation.

References

1. Thacher TD, Clarke BL. Vitamin D Insufficiency. *Mayo Clin Proc.* 2011;86(1):50-60. doi:10.4065/mcp.2010.0567.
2. Romagnoli E, Pepe J, Piemonte S, Cipriani C, Minisola S. MANAGEMENT OF ENDOCRINE DISEASE: Value and limitations of assessing vitamin D nutritional status and advised levels of vitamin D supplementation. *Eur J Endocrinol.* 2013;169(4):R59-R69. doi:10.1530/EJE-13-0435.
3. Nigwekar SU, Kroshinsky D, Nazarian RM, et al. Calciphylaxis: Risk Factors, Diagnosis, and Treatment. *Am J Kidney Dis.* 2015;66(1):133-146. doi:10.1053/j.ajkd.2015.01.034.
4. Kara C, Gunindi F, Ustyol A, Aydin M. Vitamin D intoxication due to an erroneously manufactured dietary supplement in seven children. *Pediatrics.* 2014;133(1):e240-244. doi:10.1542/peds.2013-0711.
5. Araki T, Holick MF, Alfonso BD, et al. Vitamin D intoxication with severe hypercalcemia due to manufacturing and labeling errors of two dietary supplements made in the United States. *J Clin Endocrinol Metab.* 2011;96(12):3603-3608. doi:10.1210/jc.2011-1443.